DUBLIN–(BUSINESS WIRE)–February 18, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP)
Read moreHorizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral Granules
Home »
U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
SANTA MONICA, Calif.–(BUSINESS WIRE)–Feb. 10, 2020– Kite, a Gilead Company (Nasdaq: GILD),
Read moreGenentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy
South San Francisco, CA — January 22, 2020 — Genentech,
Read moreCalifornia considers declaring common pain killer carcinogen
A fight is coming to California over whether to list
Read moreOral paclitaxel yields better outcomes than intravenous paclitaxel for metastatic breast cancer
Metastatic breast cancer patients who received an oral formulation of
Read moreMathematical model predicts drug concentration in the brain
Do medicines arrive in the right amount at the right
Read moreExcessive antibiotic prescriptions for children in low-, middle-income countries
Children in low- and middle-income countries (LMICs) are receiving an
Read moreTramadol is an odd, unpredictable opioid, scientists say
Scientists who’ve studied the curious chemistry of the opioid tramadol
Read moreConcerns about other painkillers contributed to opioid crisis, study finds
Patients with chronic pain caught between cardiovascular concerns about non-opioid
Read moreCurrent treatment for fungal meningitis is fueling drug resistance
A common first-line treatment approach for cryptococcal meningitis in low-income
Read more